Challenging Barriers to Community Oncology Care

The potential of new cancer therapies like chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody drug conjugates is exciting, but their accessibility remains a challenge. Many of these treatments are currently restricted to academic centers, leaving patients in local communities with fewer options.

At the American Society of Hematology 2023 Annual Meeting, Dipti Patel-Donnelly, MD, medical oncologist at Virginia Cancer Specialists, discussed challenges physicians and patients can face when treating hematologic malignancies in the community, as well as how to address these challenges through a co-management strategy.

Transcription:

0:09 |